Abstract

BackgroundData from interventional studies suggest that a peritoneal flap after pelvic lymph node dissection (LND) during laparoscopic, robotic-assisted radical prostatectomy (RARP) may reduce the rate of symptomatic lymphoceles in transperitoneal approach. However, most of these studies are not conducted in a randomized controlled fashion, thus limiting their scientific value. A recent prospective, randomized, controlled trial (RCT) did not show superiority of a peritoneal flap while further trials are lacking. Therefore, the aim of the presented RCT will be to show that creating a peritoneal flap decreases the rate of symptomatic lymphoceles compared to the current standard procedure without creation of a flap.Methods/designPELYCAN is a parallel-group, patient- and assessor-blinded, phase III, adaptive randomized controlled superiority trial. Men with histologically confirmed prostate cancer who undergo transperitoneal RARP with pelvic LND will be randomly assigned in a 1:1 ratio to two groups—either with creating a peritoneal flap (PELYCAN) or without creating a peritoneal flap (control). Sample size calculation yielded a sample size of 300 with a planned interim analysis after 120 patients, which will be performed by an independent statistician. This provides a possibility for early stopping or sample size recalculation.Patients will be stratified for contributing factors for the development of postoperative lymphoceles. The primary outcome measure will be the rate of symptomatic lymphoceles in both groups within 6 months postoperatively. Patients and assessors will be blinded for the intervention until the end of the follow-up period of 6 months. The surgeon will be informed about the randomization result after performance of vesicourethral anastomosis. Secondary outcome measures include asymptomatic lymphoceles at the time of discharge and within 6 months of follow-up, postoperative complications, mortality, re-admission rate, and quality of life assessed by the EORTC QLQ-C30 questionnaire.DiscussionThe PELYCAN study is designed to assess whether the application of a peritoneal flap during RARP reduces the rate of symptomatic lymphoceles, as compared with the standard operation technique. In case of superiority of the intervention, this peritoneal flap may be suggested as a new standard of care.Trial registrationGerman Clinical Trials Register DRKS00016794. Registered on 14 May 2019.

Highlights

  • Introduction and backgroundPelvic lymphoceles present a common complication after robotic-assisted radical prostatectomy (RARP) with lymph node dissection (LND) in approximately 10–18% of the cases [1,2,3]

  • The PELYCAN study is designed to assess whether the application of a peritoneal flap during RARP reduces the rate of symptomatic lymphoceles, as compared with the standard operation technique

  • Symptomatic lymphoceles are a common complication after LND

Read more

Summary

Discussion

RARP is a surgical gold standard for localized PC patients. In most cases, it is performed in combination with LND. In a thorough research including the German Clinical Trials Register and ClinicalTrials.gov, we could identify only two ongoing RCTs assessing peritoneal flaps in order to prevent or decrease lymphoceles after RARP with LND One of these is a multicenter study (DRKS00015720), whereas the other is designed single center (NCT03567525). It focuses on the difference of postoperative lymphoceles. The PELYCAN study is a parallel-group, patient- and assessor-blinded, phase III, adaptive randomized controlled superiority trial investigating the impact of PFs on symptomatic lymphoceles following RARP with LND performed by experienced surgeons beyond the learning curve.

Methods
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call